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Abstract
To advance implementation research (IR) in respiratory, sleep, and
critical care medicine, the American Thoracic Society and the
Division of Lung Diseases from the NHLBI cosponsored an
Implementation Research Workshop on May 17, 2014. The goals of
IR are to understand the barriers and facilitators of integrating new
evidence into healthcare practices and to develop and test strategies
that systematically target these factors to accelerate the adoption of
evidence-based care. Throughout the workshop, presenters provided
examples of IR that focused on the rate of adoption of evidence-based
practices, the feasibility and acceptability of interventions to patients
and other stakeholders who make healthcare decisions, the fidelity
with which practitioners use specific interventions, the effects of
specific barriers on the sustainability of an intervention, and the
implications of their research to inform policies to improve patients’
access to high-quality care. During the discussions that ensued,
investigators’ experience led to recommendations underscoring the
importance of identifying and involving key stakeholders throughout
the research process, ensuring that those who serve as reviewers
understand the tenets of IR, managing staff motivation and turnover,
and tackling the challenges of scaling up interventions across
multiple settings.
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To accelerate the research needed to address
the challenges of implementing evidence-
based care in respiratory, sleep, and critical
care medicine, the American Thoracic
Society (ATS) and the Division of Lung
Diseases from the NHLBI cosponsored an
Implementation Research Workshop on
May 17, 2014. Workshop participants are
listed in the Appendix. Both the ATS and the
Division of Lung Diseases recognized the
need to bring together an interdisciplinary
group of investigators who share a common
goal of developing methods to disseminate
the knowledge garnered from research and,
importantly, provide patients and those who
ATS/NHLBI Workshop Report S213
care for them a means of benefitting from
research that might impact their lives.
Meeting organizers sought to leverage
synergy among ATS, NHLBI, and scientists
with diverse approaches to begin to generate
a common understanding of research
priorities for future implementation
research (IR) that will further advance the
significant progress already made by
investigators working in a variety of
diseases. The purpose of this Workshop
Report is to define the key concepts in IR as
discussed during the workshop, provide
examples of IR from experienced
investigators, and describe the challenges,
recommendations, and priorities for IR in
respiratory, critical care, and sleep medicine




The National Institutes of Health funding
opportunity announcement for
dissemination and implementation research
(IR) defines IR as the “scientific study of
methods to promote the integration of
research findings and evidence-based
interventions into healthcare practice and
policy” (http://grants.nih.gov/grants/guide/
pa-files/PAR-13-055.html). Rather than
addressing whether or to what extent
healthcare interventions work, IR
investigators focus on how, where, and why
interventions impact healthcare,
considering a broad range of contexts
including participants, processes, and
places. As such, IR relies on the existing
“evidence base” for an intervention to
enable a systematic exploration of the
mechanism(s) that mediate or modify the
intervention’s effects. In contrast to IR, the
NIH announcement distinguishes
implementation as “the use of strategies to
adopt and integrate evidence-based health
interventions and change practice patterns
within specific settings.” Hence,
implementation is not merely performing
an intervention (i.e., the “action”), as it
entails the selection of the intervention with
the intention to change practice/processes.
As an example from critical care
medicine, an intensivist managing patients
on mechanical ventilation might implement
a checklist as part of the medical record that
includes evidence-based practices to assess
patients on daily rounds (e.g., low tidal
volume in those with acute respiratory
distress syndrome, sedation/daily
awakening). An implementation researcher
might consider and test alternative strategies
to accelerate the rate of adoption of the
checklist as part of rounds. In such a study,
the researcher might evaluate how well and
how quickly each strategy works. For
example, how does adding a physician
checklist as a tab in the electronic record
compare with dividing the checklist into
alerts in the electronic health record that
appear only when evidence-based practices
are not being followed? Within IR,
additional questions would include how
the rates of adoption are affected by the
time required by providers to use the
strategies, whether adoption depends on
provider attitudes regarding the strategies
(or which provider characteristics affect
their use or preference for a given
strategy), whether one strategy is more
feasible in some units (contexts) than
others, or which checklist items get
skipped by providers.
The field of IR (also referred to as
implementation science, knowledge
transfer, or knowledge translation) has
emerged to rigorously assess the methods
used to bridge the substantial gap between
advances in knowledge and “real-world”
practice. To do so, implementation
scientists may participate in a variety of
activities to measure operational differences
in practices in diverse clinical settings, to
engage a wide range of stakeholders (e.g.,
patients and their caregivers, clinicians,
healthcare organizations, payers, policy
makers) to identify their needs and barriers
to change, to assess novel technology
platforms and their potential use in specific
interventions or by specific populations,
and to evaluate the impact of linking
different types of incentives to quality
metrics that measure provider
performance.
Three types of outcome measures
have been conceptualized in IR:
implementation, service, and client
(clinical) outcomes (1). Implementation




outcomes are measured at the system
level and include efficiency, safety,
effectiveness, equity, patient-
centeredness, and timeliness. Client
(clinical) outcomes, measured at the
patient level, include satisfaction, quality
of life, physiology, function, and
symptoms, as well as mortality and
healthcare utilization.
Problem Statement
Fortunately, a proliferation of biomedical
discoveries and many new treatments for
lung disease, sleep medicine, and critical
care have emerged. Unfortunately, the
potential benefits of these breakthroughs to
individual patients have not been realized
universally. Although the challenges of
translating research into practice are not
unique to respiratory, sleep, and critical care
medicine providers, the data are staggering,
with very little (14%) new scientific
information being used in day-to-day
clinical practice within 17 years after its
discovery (2–4). Systematically assessing the
translation process is the purview of IR.
The importance of IR can be
considered from a number of vantage points
of relevance to all. For example, although
patient nonadherence is well recognized,
research more than a decade ago showed
that physicians do not adhere to evidence-
based practices for many reasons (5). More
recently, a systematic review showed
moderate evidence (at best) for existing
interventions to improve provider
adherence with asthma guidelines (6),
despite evidence that guideline-based care
is cost effective (7). Therefore, patients,
caregivers, medical providers, and payers
forego benefits when implementation of
evidence-based practices fails. IR provides
the methodological approach to determine
the mechanisms and extent to which the
translation process succeeds, fails, or
requires modifications. A systematic review
of IR is outside the scope of this ATS/
NHLBI Workshop Report; for more
information, we refer readers to other
recent reports (1, 8–11).
Many factors contribute to the barriers
to translating research findings to patient
care. Although some of the factors remain
poorly understood, one clear hindrance is
the assumption that rigorously tested
interventions from randomized controlled
trials will simply diffuse to patients
and providers (12). This assumption is
equally problematic for evidence-based
interventions that diagnose or treat disease
(e.g., medications) and those that modify
behavior, such as improving patient or
provider adherence with best practices.
Various stakeholders (e.g., patients,
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families, communities, clinicians, delivery
systems, and payers) may experience
different barriers to implementation.
Patients and families may consider
convenience (e.g., travel time or need for
transportation) and out-of-pocket costs
as critically important when making
healthcare decisions. Lack of awareness of
new research findings, limited information
about long-term outcomes, differences
between clinical trial participants and
patients in clinical practice, and resource
constraints (e.g., reimbursement by payers)
are among the factors that limit clinicians’
adoption of evidence from efficacy trials
(13). In addition, a sense of apprehension
about changes to standard practices
may hinder other clinicians. Within the
context of IR, the investigator’s role is to
understand the determinants (barriers and
facilitators) of implementation, service, and
client (clinical) outcomes and to develop
and test strategies that systematically target
these factors to accelerate the adoption of
evidence-based care.
Approaches to IR: Conceptual
Frameworks
Multiple conceptual frameworks have
been developed “to enable systematic
identification and understanding of drivers
that predict success in different settings,
guide adaption of targeted practice changes
and implementation strategies, and more
quickly and confidently build the scientific
knowledgebase” (www.isrn.net, February
19, 2014). Dozens of conceptual
frameworks have been developed to guide
IR (14). Examples discussed during the
workshop are listed in Table 1. Although no
single framework is best suited for any
particular IR question or disease, some
experts have proposed approaches that
researchers can use when selecting among
the various conceptual frameworks (11, 15).
IR Designs
Given the intent to definitively answer the
question, “Can this intervention work
under ideal circumstances?” efficacy
research is usually conducted using
standardized interventions provided to a
well-defined population in a specific
setting to maximize the precision of the
estimate of efficacy and reduce sources of
bias. Therefore, randomized clinical trials
have been the “gold standard” for
providing the highest level of efficacy
evidence in clinical research. More
recently, there has been recognition that
the determination of the “best” evidence
must account for the purpose of the
investigation (16).
If the purpose of research is to inform
how evidence is best incorporated into
decision making in day-to-day practice, the
size of treatment effects from efficacy studies
may over- or underestimate the likely
benefits or harms of interventions compared
with what is observed in clinical practice.
Such discrepancies may be due to systematic
differences in patient populations, clinician
expertise, the frequency of follow up, and
the resources available to promote treatment
fidelity and to minimize the risk of harm in
efficacy trials compared with clinical settings
(17).
In contrast to efficacy research,
effectiveness research is intended to
answer the question, “Does this
intervention work in clinical practice?”
Therefore, the study designs used in
effectiveness research should deliberately
allow for variations at the level of the
patient (e.g., range of ages or health-related
behaviors such as variable adherence to
prescribed therapy), clinician (e.g., different
levels of expertise in diagnosis and
management), setting (e.g., rural or
metropolitan and privately owned or
government-funded clinics), and system
(e.g., pay for performance or fee for service,
restricted access to specialists) that could
modify the observed harms and benefits of
interventions but reflect the variety of
situations encountered in clinical
settings (18).
IR builds on effectiveness research by
focusing more specifically on defining the
factors that will facilitate the integration of
effective practices into “real-world” patient
care settings, as well as studies comparing
different approaches to accelerating uptake
and maintenance of effective practices into
such settings. IR studies that are focused
on uncovering mechanisms governing
implementation may use both qualitative
(e.g., in situ observations of patients,
caregivers, and clinicians at the point of
care) and quantitative (e.g., surveys)
methods to define barriers and facilitators
of promoting practice change among
stakeholders (see section about stakeholders
below). If the IR question is focused on
testing different approaches to overcome
barriers or to enhance the effects of
facilitators for practice change, researchers
may use pragmatic clinical trials (using
randomization at the individual or practice
level, with interventions delivered by
clinicians rather than researchers), stepped-
wedge trials, interrupted time series, and
pre–post intervention designs (19, 20).
Given the focus of IR, the results of such
studies are likely to be heavily influenced
by the clinical and organizational context
in which IR is performed. Understanding
this context is a key aspect of IR, because
it will help to inform subsequent efforts
devoted to enact practice change in other
settings.
Engaging Stakeholders
Both effectiveness research and IR
emphasize early and continuous
Table 1. Examples of theoretical frameworks for implementation research included in
workshop presentations
Consolidated Framework for Implementation
Research (CFIR)
A resource to allow researchers to
strategically design studies with
consideration of five domains: the
intervention characteristics, the outer
setting, the inner setting, the population
characteristics (for everyone involved),
and the process of implementation.
(Originally described in Reference 24.)
Reach, Effectiveness, Adoption,
Implementation, Maintenance (RE-AIM)
A model for assessing the external validity
of implementation elements including
adoption, implementation, and
sustainability (25)
The President’s Emergency Plan for AIDS
Relief (PEPFAR): Impact evaluation
PEPFAR’s implementation science
framework for AIDS programs including
monitoring and evaluation, operations
research, and impact evaluation (26)
Promoting Action on Research
Implementation
in Health Services (PARIHS)
Examines implementation evidence around
three key elements: evidence, context,
and facilitation (27)
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stakeholder engagement. Stakeholders are
individuals or organizations that will be
affected by or have an interest in the
changes involved in a specific aspect of
care; stakeholders may include patients,
clinicians, support staff, administrators,
community leaders, and policymakers.
Stakeholders should be actively engaged in
the research process from the point of
inception and subsequent planning of the
implementation approach and research
design through execution, interpretation,
and dissemination of the results.
Stakeholders’ perspectives should be
incorporated in the research process to
ensure that the research fills the evidence
gaps they have identified as being
important (21).
For many researchers, genuinely
integrating stakeholders as partners in the
research process represents a paradigm shift
from relying on experts to decide what
research should be done, by whom, and how
and where it will be conducted. Although
such engagement can be a challenge,
stakeholder input can be critical for
identifying and removing research barriers
and improving the adoption and
sustainability of interventions after the
research is completed.
Examples of Implementation Research
Examples of IR are abundant in lung disease,
sleep-disordered breathing, and intensive
care. Examples of IR and the issues
identified by investigators at the workshop
are shown in Table 2. A variety of IR
frameworks were used by the various
investigators, depending on the
intervention, population, and clinical
setting. Although many of the studies
included client (clinical) outcomes, each





Perceptions and Recognition of
Implementation Research
Limited awareness of IR as a distinct
scientific discipline or “home” for such
activities within organizations and
institutions has broad implications,
including reduced opportunities for
training, mentoring, and infrastructure
to promote and grow collaborations
between those who develop and those
who use new health-related information.
Many investigators at the workshop
have encountered clinicians and
administrators who are unaware of IR, as
well as peers who do not recognize their
own work as falling within the spectrum
of IR.
Some investigators attending the
workshop also acknowledged that they had
not adopted a theoretical IR framework
when planning or conducting their
research. In addition, particularly for those
investigators with less training or
experience in IR, challenges included a
reluctance to use designs other than
traditional clinical trials randomized at the
level of individual patients. Such hesitation
is compounded by a lack of familiarity
about how to effectively engage
stakeholders (see below) and concerns
about how IR will be received by
institutional review boards (IRBs)
and research sponsors. For example,
cluster randomization designs (e.g.,
randomization at the practice or
organization level) may affect the
informed consent process (e.g., the
need to include both patients and
providers) (22). Cluster randomized
designs should also account for
intracluster correlation of outcomes
when developing sample size calculations
and data analysis plans (23). Pre–post
intervention studies without concurrent
controls may be useful if the time
series analysis includes a sufficiently
long preintervention period to
evaluate the possibility of preexisting
trends (19).
Engagement of Stakeholders
Researchers described numerous challenges
with respect to involving stakeholders,
including how to identify and enlist
stakeholders, negotiate among stakeholders
with varied interests, and integrate
stakeholder feedback throughout the
research process. For example, investigators
often immediately recognize patients
and healthcare providers as stakeholders
but may not as readily understand the
importance of engaging support staff within
healthcare systems (e.g., phlebotomist,
spirometry technician) and community
leaders in the planning of research, its
conduct and monitoring, and the
dissemination of research results. Other
barriers encountered by investigators with
and without an IR background included
difficulty engaging healthcare providers or
community organizations as partners.
Scale-up of Interventions
Researchers who are comfortable
conducting single-site, controlled clinical
trials often struggle with the challenges of
“scaling up” interventions across multiple,
diverse clinical settings. For example, a
program to improve adherence with cystic
fibrosis (CF) treatment conducted at 18
separate CF clinics required investigators to
balance the need for maintaining treatment
fidelity across settings with site-specific
barriers to adoption (Table 2).
Researchers have also found it
challenging to implement time-consuming
interventions within the setting of busy
healthcare systems designed for patient care,
not research. For example, primary care
providers in a healthcare system were
reluctant to participate in a study to decrease
overuse of b2-agonists because they
perceived the research as adding excessive
burden to their day-to-day clinical
workflows (Table 2). Moreover, sustaining
the use of an intervention after
implementation in a clinical setting must
compete with ongoing clinical demands
and may require changes in resource
allocation. For example, teachers can be
trained and encouraged to help parents of
children with asthma to stop smoking,
but interest and motivation may regress
unless processes are in place to ensure
sustainability (Table 2).
Design of an Implementation
Research Team
Multidisciplinary research teams (e.g.,
behavioral scientists, clinical researchers,
clinical content experts, statisticians) are
typically necessary to the conduct of IR. The
need for multiple areas of research expertise
also requires attention to communication
and management of roles, responsibilities,
and timelines. By design, IR also involves
interactions with clinical (nonresearch)
personnel and multiple other stakeholders;
changes in leadership or staff turnover can
lead to delays in completing IR.
Workshop Recommendations
Investigators participating in the workshop
identified innovative solutions to some of
the challenges inherent to IR. Table 3
provides a comprehensive list of
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suggestions to advance the field of IR in
respiratory, sleep, and critical care
medicine. Some of these recommendations
are further explained with examples in the
following text:
Identifying and Engaging Stakeholders
d Identify stakeholders at the time of
initiation of a research project. Potential
stakeholders include patients (and/or
their caregivers); patient advocacy
organizations (e.g., COPD Foundation,
CF Foundation); physician, nurses, and
other clinicians; health system
administrators and support staff, payers,
pharmacies, purchasers (e.g., employers),
community organizations,
pharmaceutical organizations, and policy
makers. Early engagement should help
to ensure that the research is relevant
to stakeholders who are critical to
sustaining the impact of an intervention.
d Engage identified stakeholders in initial
meetings in small groups to assess
interest, commitment, and ideas,
including means of identification of
additional stakeholders. As appropriate,
invite a subgroup of stakeholders to
become a part of the ongoing stakeholder
advisory committee or study
investigators, depending on availability
and interest. The extent of stakeholder
engagement needed for a particular
project is likely to depend on various
aspects of the study design, including its
target population, intervention and
comparators, outcomes, and the setting
in which the study would take place.
Meeting logistics must facilitate ongoing
stakeholder participation in planning,
execution, and evaluation of the study,
while also not over-taxing participants.
Technology can be used to reduce




d Establish early meetings with IRB
leadership, before their review of a
protocol, to introduce the project and
discuss how the specific project meets the
definition of IR and how it differs from
other types of human subjects research.
d Offer resources (e.g., publications or
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researchers’ and IRB staffs’ knowledge
about challenges and possible solutions
to these issues to facilitate the conduct
of IR. For example, provide feasible
approaches to human subject protection
in trials where it is not possible to obtain
consent from every individual.
Managing Staff Motivation
and Turnover
d Meet with all staff involved with the
project to explain the rationale and goals
of the proposed research. Maintain
frequent contact to provide updates
about the status of the project on a
regular basis. Consider identifying one or
more study “champions” to maintain
staff motivation and help with transitions
due to staff turnover.
d Commit adequate resources to develop
procedures to educate new, incoming
staff. Consider “booster” meetings to
help bring new staff up to speed and
build a cohesive team with other staff
members. Seek feedback from staff about
the study protocol and adapt the
protocol, when appropriate, based on this
feedback.
Scaling up Interventions across
Multiple Settings
d Meet “early and often” when conducting
IR projects in multiple and potentially
different settings.
d Garner support of relevant leaders and
identify study “champions” within each
healthcare system. Consider forming
“partnerships” with stakeholders at each
healthcare system to develop a sense of
community of purpose and collaborate in
identifying and overcoming barriers to
conducting the study at individual sites
or across multiple sites with similar
barriers.
d Ensure sufficient resources at individual
sites to maintain the integrity of the IR in
the context of clinical care. For example,
personnel who are involved in assessing
the implementation of an intervention
might be biased (“contaminated”) if they
were also responsible for data collection
on clinical outcomes.
d Simplify the intervention to allow
integration into routine practice and
enhance implementation. For example,
in one project primary care physicians
were able to implement complex asthma
guidelines (from a more than 400-page
evidence-based document) using care
templates that could be integrated into
more than 300 different electronic health
record systems. Field testing to ensure
the templates are user friendly for most
providers is also helpful.
d Update interventions as needed to keep
up with practice and new evidence.
Supporting Implementation Research
in Respiratory, Critical Care, and
Sleep Medicine
d Identify strategies to build capacity and
coordinate efforts among interested
researchers. Expertise in IR exists in
different research communities and
types of organizations, including the
assemblies and committees within the
ATS. Advances in the methodologies
used in IR are more likely to occur if
organizations and those who fund
research understand and emphasize the
importance of IR. Options available to
the ATS include the development of a
“home” to coordinate communication
among the various IR groups, conduct of
postgraduate training and scientific
symposia specifically for IR at national
and international meetings, and the
development of an official ATS research
statement on IR.
d Research funding by NHLBI has been
critical to the advances made to date in
IR in respiratory, critical care, and sleep.
Creation of the Center for Translation
Research and Implementation Science
(CTRIS) within the Office of the Director
at NHLBI during 2014 suggests potential
opportunities to accelerate IR activities in
collaboration with stakeholders. One
example is a recent request for
application, “Creating asthma
empowerment collaborations to reduce
childhood asthma disparities” (http://
grants.nih.gov/grants/guide/rfa-files/
RFA-HL-15-028.html). Workshop
participants expressed interest in
Table 3. Key recommendations emerging from the workshop
Integrate IR with respiratory, sleep, and critical care medicine research
Identify priority research areas
Work to adopt the nomenclature that is recognized by the field of IR
Determine how existing research infrastructure or changes to such infrastructure will
facilitate IR
Design and conduct IR
Identify relevant study designs beyond randomized clinical trials
Define appropriate control groups for IR and establish whether “usual care” is acceptable
Establish how to identify and engage stakeholders, including those who are not part of the
health care “system”
Define elements within IR that can be adapted to leverage technology to increase
dissemination
Establish how to measure adaptability
Determine how to prepare funding organizations or monitoring boards to provide an
informative review
Consider methods to enhance staff participation and motivation to minimize turnover
Measure outcomes in IR
Identify appropriate outcomes for IR
Define the metrics of success for IR
Establish the appropriate time interval and methodology to measure sustainability
Train investigators
Build a collaboration to address training guidelines (establish a curriculum) for students or
junior investigators who wish to become engaged in IR
Create programs and opportunities for established lung researchers to learn about IR
Scale up interventions across multiple settings
Identify study champions at each setting
Emphasize simplicity when proposing integration across multiple care settings
Distinguish between evidence-based care and IR
Implement and leverage supports for respiratory, critical care, and sleep IR
Develop an ATS “home” for investigators and members to coordinate and maintain
communication between various groups conducting IR
Learn about the Center for Translation Research and Implementation Science (CTRIS) at
NIH/NHLBI
Definition of abbreviations: ATS = American Thoracic Society; IR = implementation research;
NHLBI = National Heart, Lung, and Blood Institute; NIH = National Institutes of Health.
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working within NHLBI and ATS and
with other stakeholders to define and
sustain such partnerships.
Conclusions
The ATS-NHLBI IR Workshop created a
forum to bring together researchers from a
variety of research disciplines to discuss
IR in respiratory, sleep, and critical care
medicine. In so doing, participants
reviewed the components of and
approaches to IR, including a variety of
examples from their own experience. The
challenges and barriers to IR were
discussed. It is anticipated that some of
the workshop recommendations will be
taken forward via collaborative efforts to
sustain the enthusiasm for
turning research into practices that
benefit patients with lung disease and
sleep-disordered breathing and those
receiving critical care. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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